M
Description
Mabion S.A., founded in 2007 in Konstantynów Łódzki, is a fully integrated biologics CDMO providing end-to-end GMP services from cell line development to commercial production. Specializes in monoclonal antibodies, biosimilars (rituximab – first advanced biologic developed in Poland), recombinant proteins, bispecific antibodies and ADCs. Listed on the Warsaw Stock Exchange. EBRD-funded (PLN 61.4M in 2018). GMP, GLP, GCP and ISO compliant.